Page last updated: 2024-11-06

1,6-dinitropyrene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID39184
CHEMBL ID349860
CHEBI ID34066
SCHEMBL ID967910
MeSH IDM0103414

Synonyms (24)

Synonym
BIDD:ER0474
1,6-dinitropyrene
pyrene, 1,6-dinitro-
ccris 2212
brn 3413178
1,6-dinitropyrene [nitroarenes]
42397-64-8
1,6-dinitropyrene, ~60% (tlc)
1,6-dinitropyrene, 98%
FT-0639789
CHEMBL349860
chebi:34066 ,
1,6-dinitro-pyrene
unii-66q2zuf83n
hsdb 7874
66q2zuf83n ,
AKOS015913447
dinitropyrene, 1,6-
1,6-dinitropyrene [hsdb]
1,6-dinitropyrene [iarc]
SCHEMBL967910
GUXACCKTQWVTLG-UHFFFAOYSA-N
DTXSID90872819
Q27115788

Research Excerpts

Dosage Studied

1,6-Dinitropyrene dosing did not affect the levels of 8-hydroxy-2'-deoxyguanosine in these two tissues.

ExcerptRelevanceReference
" Depending on the tissue and the dosing schedule, the total level of DNA modification in animals dosed with [3H]NC was 2- to 9-fold higher than in animals dosed with [3H]AC."( Carcinogen-DNA adduct formation in the lungs and livers of preweanling CD-1 male mice following administration of [3H]-6-nitrochrysene, [3H]-6-aminochrysene, and [3H]-1,6-dinitropyrene.
Delclos, KB; Dooley, KL; Fu, PP; Kadlubar, FF; Walker, RP, 1987
)
0.47
" Unusual dose-response curves were obtained in that toxicity and genetic activity decreased at the higher concentrations examined."( The genetic activity of dinitropyrenes in yeast: unusual dose response curves for induced mitotic gene conversion.
Parry, JM; Wilcox, P, 1981
)
0.26
" In this study, rats were treated with tumorigenic doses of 1,6-dinitropyrene to establish dose-response relationships for the formation of DNA adducts in target (lung) and nontarget (liver) tissues and for the induction of 6-thioguanine-resistant mutations in spleen T-lymphocytes."( Formation of DNA adducts and induction of mutations in rats treated with tumorigenic doses of 1,6-dinitropyrene.
Beland, FA; Fullerton, NF; Heflich, RH; Smith, BA, 1994
)
0.75
" 1,6-Dinitropyrene dosing did not affect the levels of 8-hydroxy-2'-deoxyguanosine in these two tissues."( Formation of DNA adducts and oxidative DNA damage in rats treated with 1,6-dinitropyrene.
Beland, FA; Culp, SJ; Djurić, Z; Luongo, DA; Potter, DW, 1993
)
1.43
" Dose-response mutagenicity curves of 1-NP; 1,6-DNP and 1,8-DNP were obtained."( Antimutagenic activity of carotenoids in green peppers against some nitroarenes.
Gonzáez de Mejía, E; Loarca-Piña, G; Quintanar-Hernández, A, 1998
)
0.3
" A dose-response relation was not observed in the lung, white blood cells, or liver; but in the spleen lymphocytes, a threefold increase in dose resulted in approximately a twofold increase in adduct formation."( DNA adduct formation and T lymphocyte mutation induction in F344 rats implanted with tumorigenic doses of 1,6-dinitropyrene.
Beland, FA, 1995
)
0.5
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrenes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID23442Partition coefficient (logP)1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
AID200690Mutagenic activity in an Ames test on Salmonella Typhimurium TA98; Activity is log of revertants/nmol1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (99)

TimeframeStudies, This Drug (%)All Drugs %
pre-199040 (40.40)18.7374
1990's43 (43.43)18.2507
2000's15 (15.15)29.6817
2010's1 (1.01)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.12 (24.57)
Research Supply Index4.62 (2.92)
Research Growth Index4.11 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other98 (98.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]